Introduction
With the advent of platinum-based chemotherapy, advanced germ cell tumour (GCT) has been converted from a disease that was usually fatal to a potentially curable one. 1 Overall cure rates with cisplatin-based chemotherapy regimens, in conjunction with aggressive resection of residual disease, may be as high as 75%. However, even with these advances, incomplete remission, refractory disease or relapse may occur. The optimal approach for these highrisk patients is still unclear; options include salvage chemotherapy, radiation therapy and surgery to debulk remaining tumour mass. Several non-randomized studies have examined the role of high-dose chemotherapy with autologous blood or marrow transplantation in the salvage setting (auto-SCT). [2] [3] [4] [5] These studies suggest that auto-SCT can induce CR and prolonged disease-free survival. 2, 6, 7 One randomized controlled trial comparing standard salvage chemotherapy with auto-SCT showed no significant benefit from auto-SCT. 8 However, median follow-up in this study was relatively short (45 months, range 22 days to 7.5 years). Recent cohort studies 9 have shown that sequential auto-SCT (multiple cycles of high-dose chemotherapy each followed by stem cell infusion) may be a preferable option to single auto-SCT. 9, 10 We present the results of a cohort of 71 patients who received a single auto-SCT for GCT at two Canadian transplant centres. Uniquely, we were able to examine very long-term outcomes including late toxicities and relapses.
Materials and methods
The Leukemia/Bone Marrow Transplant Programme at the British Columbia Cancer Agency and the Blood and Marrow Transplant Programme at CancerCare Manitoba have the responsibility of evaluating and treating all candidates for haematopoietic transplantation in the Canadian provinces of British Columbia and Manitoba, respectively. Both these programmes prospectively record detailed demographic and clinical data for transplant patients. Using these data, we identified all patients who underwent auto-SCT for advanced seminomatous or nonseminomatous GCT between March 1986 and February 2004. Both sites are based at academic centres; in these settings, both transplant physicians and genitourinary medical oncologists were closely involved in the management, including long-term follow-up, of each patient.
Eligibility criteria for auto-SCT included demonstration of adequate organ function as per individual institutional policies. Each patient provided written informed consent for therapy. Pre-transplant workup included pertinent history, physical examination, complete blood count, biochemistry, tumour marker levels (alpha fetoprotein, beta-human chorionic gonadotrophin and/or lactate dehydrogenase), and appropriate radiological imaging (usually computed tomography scans), chest X-ray, electrocardiogram, radionuclide ventriculogram, pulmonary function tests, creatinine clearance and others, as indicated. Tissue biopsies were mandated for diagnostic purposes when clinically indicated, especially when relapse or refractory disease was suspected in the setting of normal tumour markers.
Individual patient records were reviewed for demographic information, GCT classification prognostic group at initial diagnosis, initial treatment, response to treatment, salvage treatment, response to salvage treatment, disease status at auto-SCT and post auto-SCT outcomes, including treatment-related toxicities, relapse and death.
All patients had been initially treated with standard regimens containing cisplatin plus some combination of etoposide, vincristine, vinblastine and/or bleomycin, depending on the preferred treatment protocol of the referring oncology centre. Selected high-risk patients proceeded straight to high-dose chemotherapy and auto-SCT after documentation of an incomplete response to first-line chemotherapy. The remaining patients achieved acceptable responses to initial therapy only to have clear evidence of relapse either by radiological or tumour marker progression. All patients received salvage chemotherapy again with cisplatin-containing regimens and, on demonstration of chemosensitivity, were considered as candidates for auto-SCT. At both CancerCare and the British Columbia Cancer Agency, a multidisciplinary team was involved in the decision to proceed to auto-SCT, involving both transplant physicians and medical oncologists. The medical oncologists were involved in patient selection based on disease status, whereas transplant physicians ensured that sufficient stem cells could be collected and that patients could tolerate the transplant process itself. All patients received a single auto-SCT.
High-dose chemotherapy for patients with non-seminomatous histology was etoposide 3.0 g/m 2 , ifosfamide 6.0 g/ m 2 or CY 50 mg/kg and carboplatin 0. . Thawed cryopreserved autologous marrow or G-CSF-mobilized peripheral blood haematopoietic stem cells were re-infused on day 0, no earlier than 72 h after the last dose of carboplatin and 48 h after the last dose of CY.
Patients were accommodated in specialized BMT inpatient wards with high efficiency particulate air-filtered rooms. Viral and fungal prophylaxis was with acyclovir or valacyclovir and low-dose amphotericin B or fluconazole, respectively. Empirical broad-spectrum i.v. antibiotics were initiated for management of neutropenic fever. Post auto-SCT pneumocystis pneumonia prophylaxis consisted primarily of trimethoprim/sulphamethoxazole.
OS was calculated from the day of auto-SCT until death from any cause. EFS was calculated from the day of auto-SCT until relapse from GCT or death from any cause. TRM was defined as any death not directly attributable to GCT within 100 days of auto-SCT. Probabilities of OS and EFS were calculated using the Kaplan-Meier product limit estimate. The log-rank test was used for univariate analysis of prognostic factors. A P-value of 0.05 was considered significant. Cox regression was used for univariate analysis, and factors predictive of outcome were included in a multivariate analysis. SPSS version 17.0 (SPSS for Macintosh, Release 17.0.; SPSS Inc., Chicago, IL, USA) was used for all calculations.
Patients were staged at diagnosis according to the International Germ Cell Consensus Classification (IGCCC) staging system. 11 We also applied the Indiana prognostic scoring system to the current patient cohort in order to predict post auto-SCT outcomes. 9 The Indiana model assigns three points to patients on third-line or greater chemotherapy, two points to patients refractory to platinum therapy and two points for having high-risk disease according to the IGCCC. Patients with no points were considered to be at low risk, and patients with more than four points were considered to be at high risk.
The Research Ethics Boards of the Universities of Manitoba and British Columbia approved this study.
Results
A total of 71 patients, all of whom were male, underwent auto-SCT at British Columbia Cancer Agency (n ¼ 54) or CancerCare Manitoba (n ¼ 17) between 1 March 1986 and 28 February 2004. Demographic data for all patients are included in Table 1 . The median age was 31 years (range 16-58 years). A total of 67 of the patients had nonseminomatous GCT and 4 had seminomatous GCT. A total of 57 patients had primary gonadal disease and 14 had primary extragonadal disease. Of the latter, 11 patients presented with primary mediastinal disease, 2 presented with primary central nervous system disease and 1 presented with retroperitoneal disease.
In all, 28 patients underwent auto-SCT for relapsed disease after achieving an initial CR. Of these, 24 patients underwent auto-SCT after a first relapse, whereas 4 patients underwent transplant after a second relapse. An additional 36 patients achieved only an incomplete response after initial therapy and proceeded to auto-SCT after salvage chemotherapy for active residual disease. None of these 36 patients received auto-SCT as consolidation therapy. That is, all had active disease that rendered them eligible for transplantation. The remaining seven patients had disease that was progressive after initial therapy (primary refractory disease), and they proceeded to auto-SCT after salvage chemotherapy.
Incomplete response, relapse or refractory disease was diagnosed based on abnormal imaging findings combined with elevated tumour markers in 59 patients (83%). The remaining 12 patients who did not have elevated tumour markers underwent biopsy to confirm the presence of residual GCT. In nine (13%) patients, surgery was used in addition to salvage chemotherapy and auto-SCT in the management of relapsed or refractory GCT.
Complete IGCCC staging information was available for 64 patients. At diagnosis, 18 (28%) patients had good prognosis, 13 (20%) had intermediate prognosis and 33 (52%) had poor-risk disease. A total of 50 patients had disease that was still responding to chemotherapy (at least a PR with the previous salvage cycle of chemotherapy), whereas 21 had disease that was not responding to salvage chemotherapy at the time of auto-SCT. Progenitor cells were obtained from the peripheral blood in 31 (44%) patients, BM in 38 (54%) and from both sources in 2 (3%) patients. At the time of analysis, surviving patients had been followed up for a median of 10.1 years (range 2-15 years).
OS at 5 years was 44.7% (95% confidence interval (CI) 32.9-56.5%) and EFS was 43.5% (95% CI 31.4-55.1%).
At 10 years, OS was 37.1% (95% CI 25.1-39.1%) and EFS was 33.8% (95% CI 20.8-36.8%). A total of 33 patients eventually relapsed after auto-SCT. Of those 33, 30 relapsed within the first year after transplant, one relapsed between the first and second year and two patients relapsed after 10 years. The first of these very-late-relapsing patients developed an abdominal mass 13 years after auto-SCT. This mass was biopsied and confirmed to be a recurrence of GCT. He was subsequently started on chemotherapy consisting of vinblastine, ifosfamide and cisplatin. The mass initially responded to chemotherapy, but after 3 months of chemotherapy, began to increase in size. No additional therapy was offered, and this patient subsequently died. The second patient relapsed 11 years after auto-SCT. This patient developed new-onset retroperitoneal lymphadenopathy associated with a rising alpha fetoprotein. A biopsy was performed, and findings were consistent with recurrence of GCT. The mass was surgically removed and the patient is clinically stable 2 years after recurrence.
Nine patients died as a result of treatment, resulting in a TRM of 12.6%. The majority of these patients died as a result of infectious complications. In addition, three patients developed secondary malignancies. One patient developed osteogenic sarcoma 3 years after auto-SCT, one developed gastric adenocarcinoma 13 years after auto-SCT and another developed an astrocytoma 7 years after auto-SCT. Thus, the incidence of secondary malignancies was 4.2%.
In a Cox univariate analysis, three variables were found to be associated with increased mortality (Table 2) . Disease resistant to salvage chemotherapy (less than a partial response to the last chemotherapy cycle) was the most significant prognostic factor, with a hazard ratio (HR) of 3.25 (95% CI 1.71-6.17; Po0.001). IGCCC high-risk disease at the time of diagnosis was also associated with a worse outcome (HR 2.43, 95% CI 1.31-4.52; P ¼ 0.005). Finally, primary mediastinal disease had a HR of 2.07, with borderline statistical significance (95% CI 0.95-4.50; P ¼ 0.06). Other variables, such as tumour histology, age, elevated human chorionic gonadotrophin at diagnosis and elevated alpha fetoprotein at diagnosis were not associated with a worse outcome. Kaplan-Meier plots of OS were created with patients stratified according to chemosensitivity, IGCCC risk and primary mediastinal disease (Figures 1-3) . Disease that was resistant to salvage chemotherapy was associated with worse prognosis (Po0.001), as was IGCCC high-risk disease (P ¼ 0.03). Primary mediastinal disease was not significantly associated with a worse prognosis (P ¼ 0.06). A Cox multivariable regression was also performed, with covariates including chemosensitivity pre auto-SCT, IGCCC disease risk and primary mediastinal disease (Table 3 ). In this model, high-risk disease at diagnosis had a HR of 2.45 (95% CI 1.23-4.89), disease resistant to chemotherapy had a HR of 2.98 (95% CI 1.52-5.85) and primary mediastinal disease had a HR of 0.95 (HR 0.40-2.27).
We applied the Indiana prognostic model for GCT patients undergoing auto-SCT, and achieved similar results to that of the original study. 9 In our cohort, Indiana highrisk patients had an OS of o10% at 5 years, whereas lowrisk patients had an OS of 460% at 10 years.
Discussion
Auto-SCT for GCT provides sustained remissions in some patients with refractoriness to first-line therapy or as salvage therapy in patients who have relapsed after initial standard-dose chemotherapy. However, the benefit observed comes at a cost of significant TRM and secondary malignancies. Our dual-centre, population-based cohort demonstrates several useful points that clinicians should be aware of when considering auto-SCT for GCT.
The OS of 37.1% and EFS of 33.8% at 10 years is comparable with previous studies. 4, [12] [13] [14] [15] A summary of the results of the larger studies, in which the majority of patients received auto-SCT for relapsed GCT, is shown in Table 4 . Previous studies have demonstrated an OS of between 25 4 and 57%. 13 However, these studies have all had varying lengths of follow-up, with different treatment protocols and patient populations. In our study, the median follow-up of patients at the time of analysis was 410 years; this is the longest follow-up of patients undergoing single auto-SCT for GCT reported in the literature to date. This extended follow-up demonstrates that a substantial portion of patients with relapsed or refractory GCT can achieve a prolonged and sustained remission.
The most important predictor of outcome is sensitivity to second-line chemotherapy at time of auto-SCT (HR 3.25; Po0.001). This finding is consistent with previous studies. 4, 8, 9, 14, 18, 19 In addition, in those presenting with primary mediastinal disease, auto-SCT was associated with relatively poor OS and EFS. A large review of patients published in 1996 by Beyer et al. 20 had no long-term survivors after auto-SCT in patients with primary mediastinal presentation. Our study did show one long-term survivor, but there was a trend towards a worse prognosis in this small subgroup. In addition, IGCCC disease risk at presentation was predictive of OS and EFS, as has been previously reported. 4, 9, 18, 20 The majority of relapses occurred within 1 year. However, there were two very late relapses (11 and 13 years after auto-SCT). Very late relapse does occur with GCT; 21, 22 the largest series to date consisted of 47 patients who relapsed 45 years after initial treatment. 23 Late relapse has not been previously reported in patients undergoing auto-SCT for GCT. The cohort described in this paper has had a considerably longer follow-up than other previously reported cohorts, and thus is uniquely positioned to detect late relapses. As late relapse may occur after initial treatment, it is not surprising that it would also be noted after treatment with auto-SCT. Our observation of a good outcome in the patient whose late relapse was amenable to resection, but not in the patient who was given chemotherapy alone, also corresponds well with the available literature. Late relapses appear particularly resistant to chemotherapy.
The treatment-related mortality in our study was 12.6%, comparable with previous studies (see Table 4 ). The proportion of secondary malignancies in this cohort was 4.2%. This is somewhat higher than has been reported in previous studies; Houck et al.
24 reported a 2.6% incidence of secondary malignancies in a cohort of 113 patients and Einhorn et al. 9 reported an incidence of 1.6% in a cohort of 182 patients. However, given the prolonged follow-up in our study, a higher incidence of secondary malignancies would be expected. It is pleasing to note that no patient in our cohort developed therapy-related myelodysplasia or acute leukaemia, suggesting that the high-dose regimens that we used did not result in excess haematopoietic stem cell toxicity.
The possibility of very late relapses and second malignancies are reminders of the need for long-term follow-up of GCT patients. We suggest annual clinical review, with particular attention to cardiovascular risk factors, status of the remaining testis, a search for a late relapse or second primary malignancy and blood tests that should include alpha fetoprotein and human chorionic gonadotrophin. However, we do not recommend routine surveillance computed tomography scans in order to avoid further risks of second malignancy.
Recent interest has focused on the use of tandem auto-SCT in patients with relapsed or refractory GCT. A large single-centre study published by Einhorn et al. 9 demonstrated an OS of 460% at a median follow-up of 48 months, a result superior to that of our cohort. This additional benefit may reflect the use of tandem auto-SCT, as compared with single auto-SCT, or may relate to differences in the underlying patient population. One trial randomized patients to either single auto-SCT or sequential auto-SCT. 10 This study was stopped early after the randomization of 216 patients, owing to increased toxicity in the single transplant arm, but failed to show a benefit in OS or EFS to sequential auto-SCT. Furthermore, a registry-based study failed to show a reduction in relapse rate or a survival advantage for planned tandem auto-SCT as against single auto-SCT for high-risk GCT. 25 There has not been a randomized trial comparing tandem auto-SCT with standard-dose chemotherapy in patients with relapsed GCT, and this remains an area of controversy. In addition, targeted agents have shown benefit together with cytotoxic chemotherapy, 19 and the role for these therapies with or without auto-SCT in relapsed GCT still remains to be determined.
A limitation of this study is that we were unable to systematically document ototoxicity and neurotoxicity, complications that might be expected after extensive exposure to cisplatin and/or carboplatin. Such complications may have significant impact on quality of life, and we recommend that future studies ensure that they be described.
In this cohort of 71 patients primarily with relapsed or refractory GCT who were followed up for 410 years, auto-SCT was able to provide a sustained relapse-free survival interval in a substantial number of patients. Benefit after auto-SCT was particularly noticeable in patients with disease that was still responding to second-line chemotherapy and without primary mediastinal presentation. The prognostic model developed by Einhorn et al. 9 was able to predict OS in our cohort, and may be of use to select patients for auto-SCT. Oncologists and primary care providers should be aware that late relapses, even beyond 10 years, can occur in patients with initially excellent responses to auto-SCT. Further study is required to determine how sequential auto-SCT compares with a single auto-SCT or with standarddose chemotherapy, and the impact that novel agents have in this patient population.
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